单次与多次膀胱灌注方案对原发性上尿路尿路上皮癌术后预后的影响

摘要/Abstract

摘要：

目的: 探讨单次与多次膀胱灌注方案对上尿路尿路上皮癌（UUT-UC）术后患者的疗效和安全性。方法: 收集本院2010年6月至2016年7月收治的原发性上尿路尿路上皮癌术后患者63例，根据化疗方案分为单次膀胱灌注组（SIG）和多次膀胱灌注组（RIG）。比较两组无进展生存期（PFS）、总生存期（OS）和近期毒副反应。结果: 全组随访5～60个月，中位随访36.4个月。SIG和RIG 3年、5年OS分别为65.5%、51.7%和67.6%、52.9%，二者比较差异无统计学意义（P>0.05）；3年、5年PFS分别为79.3%、72.4%和85.3%、76.5%，两组PFS差异有统计学意义（P<0.05）。两组不良反应主要以1～2级的血液学毒性反应和消化道反应为主。RIG在血液学毒性方面发生率明显高于SIG，差异有统计学意义（P<0.05）。消化道反应及膀胱痉挛、膀胱炎方面，RIG高于SIG，两组比较差异有统计学意义（P<0.05）。肝、肾功能损害及发热方面，两组比较差异无统计学意义（P>0.05）。结论: 吡柔比星在UUT-UC术后膀胱预防灌注化疗临床是安全有效的，多次灌注化疗较单次可减少膀胱肿瘤复发率，但不能提高总生存时间。但多次灌注方案引起更严重的消化道反应和血液学毒性反应。

关键词: 上尿路尿路上皮癌, 膀胱灌注, 多周期, 预后

Abstract:

AIM: To compare the effect and safety between single intravesical chemotherapy and repeated instillation intravesical after radical nephroureterectomy in upper urinary tract urothelial carcinoma (UUT-UC). METHODS: 63 patients were enrolled after radical nephroureterectomy in upper urinary tract urothelial carcinoma from June 2010 to July 2016, and were divided into two groups according to the chemotherapy protocol. 29 patients in single intravesical group (SIG) and 34 patients in repeted instillation intravesical group (RIG). The progression-free survival, overall survival and side effects between two groups were compared.RESULTS: Follow-up was 5-60 months, media follow-up was 36.4 months. The 3-year and 5-year OS in SIG and RIG were 65.5%, 51.7% and 67.6%, 52.9%, respectively. No significant difference was observed between them(P>0.05). Meanwhile, the 3-year and 5-year PFS in SIG and RIG were 79.3%，72.4% and 85.3%，76.5%, there were significant differences between them(P<0.05). The main side effects of two groups were 1-2 grade hematologic toxicity and gastrointestinal reaction. The incidence of hematologic toxicity, digestive tract reaction, bladder spasm and cystitis in RIG were higher than SIG, there were significant difference among them(P<0.05).However, there were no significant difference between liver or kidney damage and fever(P>0.05).CONCLUSION:Using pirarubicin for intravesical instillation is safe and effective for UUT-UC patients after radical nephroureterectomy. Compared with single instillation, repeated instillation chemotherapy can reduce the recurrence rate of bladder cancer, whilst cannot improve the overall survival. Also, repeated instillation cause more severe gastrointestinal and hematologic toxic reactions.

Key words: upper urinary tract urothelial carcinoma, intravesical instillation, repeated instillation, prognosis

中图分类号:

R737

廖国栋，俞蔚文，张琦，吕佳，毛祖杰. 单次与多次膀胱灌注方案对原发性上尿路尿路上皮癌术后预后的影响[J]. 中国临床药理学与治疗学, 2017, 22(4): 461-465.

LIAO Guodong, YU Weiwen, ZHANG Qi, LV Jia, MAO Zujie. Effect of single and repeated intravesical instillation on prognosis after radical nephroureterectomy in upper urinary tract urothelial carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 461-465.

参考文献

［1］Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017［J］. CA Cancer J Clin , 2017,67(1):7-30.
［2］Chen W, Zheng R, Baade PD, et al.Cancer statistics in China,2015［J］.CA Cancer J Clin, 2016,66(2):115-132.
［3］廖洪,李汉忠,张玉石等.单中心尿路上皮癌2115例临床特点分析［J］.中华泌尿外科杂志,2014,35(12):900-904.
［4］Xylinas E, Rink M, Margulis V, et al. Multifocal carcinoma in situ of the upper tract is associated with highrisk of bladder cancer recurrence ［J］. Eur Urol,2012,61(5):1069-1070.
［5］Zigeuner RE,Hutterer G,Chromecki T,et al.Bladder tumor development after urothelial of the upper urinary tracts related to primary tumor location［J］. BJU Int,2006,98(6):1181-1186.
［6］Li WM, Shen JT, Li CC, et al. Oncologicoutomes following three different approaches to the distal ureter and bladdercuff in nephroureterectomy for primary wpper urinary tract urothelialcarcinoma ［J］ . Eur Urol，2010,57(6):963-969.
［7］Xylinas E, Kluth L, Passoni N, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool［J］. Eur Urol, 2014,65(3):650-658.
［8］Milojevic B,Djokic M,Sipetic-Grujicic S, et al. Bladder cancer after managing upper urinary tract transitional cell carcinoma:risk factors and survial［J］. Int Urol Nephrol, 2011,43(3):729-735.
［9］Xiong G, Chen X, Li X, et al. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients ［J］. J Formos Med Assoc. 2014,113(8):521-526.
［10］Chen XP,Xiong GY,Li XS,et al.Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma:experience from a nationwide high-volume centre in China［J］.BJU Int,2013,112(7):917-924.
［11］Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan［J］. Proc Natl Acad Sci USA,2012,109(21): 8241-8246.
［12］Ni S, Tao W, Chen Q, et al. Laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes ［J］. Int Braz J Urol,2013,39(6):817-822.
［13］Zou L, Zhang L, Zhang H, et al. Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopicnephroutetectomy for upper tract urothelial carcinoma［J］. World J Urol,2014,32(2):565-570.
［14］Fang D, Li XS, Xiong GY, et al. Prophylactic intravesical chemotherapy to prevent bladder tumora after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis［J］. Urol Int,2013,91(3):291-296.
［15］Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial［J］.J Clin Oncol,2013,31(11):1422-1427.
［16］Wu WJ, Ke HL, Yang YH, et al. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy ［J］?J Urol,2010,183(1):56-61.
［17］Liu YQ,Lu J, Hong K, et al. Independent prognostic factors for initial intravesical recurrence after laparosocopic nephroureterectomy for upper urinary tract urothelial carcinoma［J］.Urol Oncol,2014,32(2):146-152.
［18］Xylinas E,Rink M,Cha EK,et al.Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper urinary tract urothelial carcinoma［J］.Eur Urol,2014,65(1):201-217.
［19］Fang D, Zhang L, Li X, et al. Presence of concomitant non-muscle-invasive bladder cancer in Chinese patients with upper urinary tract urothelial carcinoma: risk factors, characteristics, and predictive value［J］. Ann Surg Oncol,2015,22(8):2789-2798.
［20］Gakis G, Witjues JA, Comperat E, et al. EAU guideline on primary urethral carcinoma［J］. Eur Urol,2013,64(5):823-830.
［21］Kobayashi Y, Saika T, Miyaji Y,et al. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma［J］. World J Urol,2012,30(2):271-275.
［22］Cho DS, Kim SI, Ahn HS, et al. Predictive factors for bladder recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma［J］.Urol Int,2013,91(2):153-159.
［23］Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems［J］.J Pharm Pharmacol,2013,65(2):157-170.

[1]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[2]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[3]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[4]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[5]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[6]	许宏磊, 徐炳欣, 俎青, 赵艳, 高朋飞, 于洋. CYP2C19基因多态性对老年急性脑梗死患者应用氯吡格雷临床预后的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1014-1020.
[7]	汪向海, 邢敏, 吕镗烽, 刘红兵, 宋勇. 敲降长链非编码RNA 00467表达对肺腺癌患者预后的影响及其机制[J]. 中国临床药理学与治疗学, 2020, 25(8): 841-849.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	蔡江怡，刘耀，李嘉诚. 膀胱灌注透明质酸钠治疗间质性膀胱炎的温度选择[J]. 中国临床药理学与治疗学, 2020, 25(4): 447-454.
[10]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[11]	方川川，倪观太，金兰, 刘记, 刘晓庆，乔春, 罗永红. PEA-15 磷酸化状态与卵巢上皮性癌预后的相关分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 523-528.
[12]	白艳，郑晓永，杨雅阁，方立峰. 程序性死亡配体1基因遗传变异对术后结直肠癌患者接受5-FU为基础辅助化疗预后的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 180-187.
[13]	李文书，董淮富. 血清降钙素原在细菌性脑膜炎中的价值[J]. 中国临床药理学与治疗学, 2019, 24(11): 1315-1320.
[14]	李晓洁，张胜威，王华胜，王东，梅家转，邓业巍. VEGF-A基因多态性对接受氟尿嘧啶为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(8): 900-904.
[15]	单艳，李志刚. TNFAIP3基因遗传变异对食管鳞癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(7): 820-824.